{
  "id": "5e30f417fbd6abf43b000043",
  "type": "yesno",
  "question": "Is Apremilast effective for Beh\u00e7et\u2019s Syndrome?",
  "ideal_answer": "Yes, Apremilast is effective for Behcet's Syndrome",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27163156",
    "http://www.ncbi.nlm.nih.gov/pubmed/31722152",
    "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
    "http://www.ncbi.nlm.nih.gov/pubmed/31609785"
  ],
  "snippets": [
    {
      "text": "AREAS COVERED: This review provides a digest of all current experience and evidence about pharmacological agents recently described as having a role in the treatment of BS, including interleukin (IL)-1 inhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon-alpha-2a, and apremilast.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27163156",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nApremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nApremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In patients with oral ulcers associated with Beh\u00e7et's syndrome, apremilast resulted in a greater reduction in the number of oral ulcers than placebo but was associated with adverse events, including diarrhea, nausea, and headache. (",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31722152",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast is now approved for the treatment of oral ulcer of Beh\u00e7et syndrome in the United States.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31609785",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}